Your selection
NoneFilter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Biogen Appoints Chuck Triano as Head of Investor Relations
March 14, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … and plans and the potential of our commercial business and pipeline programs; capital allocation and investment … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
March 8, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … of, and expectations for, our commercial business and pipeline programs; capital allocation and investment … actions to improve risk profile and productivity of R&D pipeline, collaborations, and business development …
Biogen and Sage Therapeutics Share Update on FDA Advisory Committee for Zuranolone
March 8, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … and PPD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
March 5, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 27, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen to Participate in the Cowen 43rd Annual Health Care Conference
February 20, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 6, 2023 - … and PPD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated … and PPD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated … and PPD; the potential of Biogen’s commercial business and pipeline programs, including zuranolone; the anticipated …
Lecanemab Receives Priority Review Status in Japan
January 29, 2023 - … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and …
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
January 26, 2023 - … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and …
